Nordic healthcare technology specialist is looking to expand its footprint in the UK following the success of its Hepatitis information system HepCARE
August 2023 – BCB Medical, a software and medical data company, is set to showcase its clinical information management system (CIMS) for the first time in the UK at HETT23, the UK’s leading healthcare technology and digital health event.
HETT23 will take place on the 26th and 27th September at ExCel London. The two-day show brings together more than 4,500 healthcare and technology professionals to enable meaningful collaboration and innovation across the heath and care sector. BCB Medical will be presenting its disease specific CIMS, which are able to monitor and analyse different disease groups by using clinically evaluated medical devices for healthcare professionals.
Offering a seamless digital service for patients, citizens and organisations in healthcare and social services, BCB’s CIMS automatically collects, manages and evaluates data on specific diseases. This helps specialist teams to understand how they present in different patients, how they interact with other conditions, and the best treatment plans based on individual criteria. It has already had a positive impact on the efficiency of treatments in over 400 clinics across Finland, Sweden, Denmark, Norway and the UK.
BCB will use HETT23 to launch its CIMS to the UK market for the first time. It follows the success of HepCARE, BCB’s hepatitis decision support system that is already in situ at 29 Trusts across the UK.
Speaking on his experience with HepCARE, Stephen Ryder, Consultant Physician in Hepatology and Gastroenterology at The Park Hospital and the Nottingham Digestive Diseases Centre and Biomedical Research Unit said: “We have used HepCARE to contribute to a large national data cohort in Hepatitis B, the NIHR Health Information Collaborative, which shares data across a number of centres in UK. The outputs are designed to inform service improvement, for example, studying the impact of the COVID pandemic on Hepatitis B follow-up”.
“On a local level it is used for audits and service evaluation including access to care for these patients. We can also do powerful things with the data in clinical practice. To diagnose liver fibrosis there are a number of parameters including bloods and fibroscan. With HepCARE you can easily generate all these markers to predict and decide liver status. I also realised I never look at most of these values on their own, but in the consolidated view, it is very impactful.”
Emma Höglund, Head of International Expansion at BCB Medical added: “We want to change the way that clinicians use clinical data in their everyday work, by providing simple and holistic view of various data sources in the same place, enabling predictive decision support while saving time and resource. We strongly believe that by equipping clinicians with seamless tools to make more informed decisions will ultimately improve outcomes for both existing and future patients.”
